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OBJECTIVES In the Heparin in Early Patency (HEAP) pilot study a beneficial effect of high-dose heparin
on early patency in acute myocardial infarction (MI) was observed in a matched-control study.
BACKGROUND High dose bolus intravenous injection of heparin may achieve lysis of coronary thrombi and
could enhance early patency of the infarct related vessel in patients with MI scheduled for
primary angioplasty.
METHODS Before primary angioplasty, 584 patients with MI entered an open randomized trial of high
dose (300 IU/kg) or low dose (0 or 5,000 IU) heparin. Of the 584 patients, 299 were
randomized to high dose and 285 patients to low dose heparin.
RESULTS Thrombolysis In Myocardial Infarction (TIMI) flow grade 2 or 3 was observed before
primary angioplasty in 65 patients (22%) in the high dose group and 60 patients (21%) in the
low dose heparin group (p . 0.1), whereas TIMI flow grade 3 was observed in 38 (13%) and
24 patients (9%), respectively (p 5 0.11). There were no differences in the clinical end points
between the two groups. There were no hemorraghic strokes, while 10% of the patients in the
high dose group required blood transfusion versus 6% in the low dose/no heparin group (p 5
0.07). No subsets of patients showed beneficial effects of high dose heparin, such as patients
with longer delay between heparin administration and diagnostic angiogram or patients with
short delay between symptom onset and admission.
CONCLUSIONS There is no benefit of high dose bolus heparin on early patency compared with no or low dose
heparin. (J Am Coll Cardiol 2000;35:600–4) © 2000 by the American College of
Cardiology
Early coronary reperfusion is the primary goal of the initial
treatment for patients with acute myocardial infarction
(MI). Primary angioplasty is a highly effective reperfusion
therapy in patients with MI, resulting in more complete and
sustained patency rate of the infarct related artery than in
patients treated with thrombolytic therapy (1). Primary
angioplasty, however, is associated with an increased delay
between admission and start of treatment, in particular
when patients are admitted to community hospitals and are
transferred to an angioplasty center. Adjunctive therapy
given in the delay before angioplasty, without compromis-
ing the angioplasty result, would be desirable. Adjunctive
therapy may induce reperfusion, and this may limit myo-
cardial injury before primary angioplasty is performed. In
thrombolytic therapy with alteplase, higher early angio-
graphic patency was shown when intravenous heparin was
given as an adjunct therapy (2). Heparin gives a dose
dependent reduction in the deposition of platelets and fibrin
and in the incidence of macroscopic thrombosis in pigs (3).
In the Heparin in Early Patency (HEAP) pilot study, a high
intravenous dose of heparin (300 IU/kg) was given together
with aspirin, to study the effect on early patency (4). In this
matched control study, in 51% of patients Thrombolysis In
Myocardial Infarction (TIMI) flow grade 2 or 3 was
observed, whereas in control patients TIMI flow grade 2 or
3 was seen in only 18% (p , 0.001). These findings needed
to be evaluated in a randomized controlled trial.
METHODS
The protocol was approved by our institutional review
board. Patients with MI presenting within 6 h after symp-
tom onset, or those presenting within 24 h if they had
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evidence of ongoing ischemia, were included in this trial.
The age limit was 75 years. Electrocardiographic criteria
were ST segment elevation of $2 mm in two or more
contiguous leads. Patients with contraindications to heparin
(active bleeding, history of stroke ,3 months, recent major
surgery) or with MI after recent angioplasty were excluded.
After informed consent, patients were randomized. A hep-
arin bolus was administered according to the outcome of
randomization. The standard therapy consisted of aspirin
(500 mg intravenously or 300 mg orally) and intravenous
nitroglycerine. Patients were recruited at the emergency
department of our angioplasty center or referred from
hospitals without angioplasty facilities for primary angio-
plasty. Transferred patients were referred from 11 commu-
nity hospitals in the region, which are localized at travel
distances ranging from two to 40 miles. The heparin bolus
was administered at the referral hospital prior to transpor-
tation to our angioplasty center. Patients admitted directly
to the angioplasty center were brought immediately to the
coronary care unit where the heparin bolus was adminis-
tered. The heparin dose for the group of patients random-
ized to high dose either at the referral centers or the
angioplasty center was 300 IU/kg body weight, adminis-
tered as a single intravenous bolus. Referred patients ran-
domized to the control group received 5,000 IU heparin
bolus before transportation, while control patients admitted
directly to the angioplasty center received no heparin before
catheterization. No thrombolytics or glycoprotein IIb/IIIa
blockers were given. The patients were transferred as soon
as possible to the catheterization laboratory, and coronary
angiography was performed according to standard proce-
dures. Preprimary angioplasty patency was scored according
to TIMI flow grade by two cardiologists blinded to the
treatment allocation. Primary angioplasty was performed on
indication, and before this procedure, a bolus heparin with
a dosage of 5,000 IU was given. Primary angioplasty was
considered successful if the residual stenosis of the infarct
related artery was less than 50% and TIMI flow grade 3 was
present after the procedure. Heparin infusion was given
after the procedure for 24 to 48 h in a dose titrated to
achieve an activated partial thromboplastin time between
two and three times the normal value (5). Patients were not
treated with primary angioplasty if extensive coronary artery
disease was found or there was involvement of the left main
coronary artery that made urgent coronary bypass surgery
necessary. If no infarct related artery could be identified and
no reperfusion therapy was indicated, conservative treat-
ment followed. Standard therapy consisted of aspirin (80 mg
daily), beta-adrenergic blocking agents, if tolerated, and
angiotensin-converting enzyme blockers and cholesterol-
lowering drugs on indication. Patients randomized to high
dose heparin at the referral hospital and at the angioplasty
center were compared with patients who received 5,000 IU
heparin at the referral hospital and patients who received no
heparin at the angioplasty center.
Data collection. Demographic data and risk factor data
were recorded at baseline. The primary end point was the
patency of the infarct related artery at diagnostic angiogra-
phy. All angiograms were reviewed by two cardiologists,
blinded for treatment allocation and clinical data. At dis-
charge, left ventricular ejection fraction (LVEF) was mea-
sured with a radionuclide technique as previously described
(5). All major cardiovascular events during hospital admis-
sion were documented. Major bleeding was defined as blood
loss, requiring blood transfusion. Enzymatic infarct size was
determined by measurements of lactate dehydrogenase as
reference enzyme (LDHQ72). Cumulative enzyme release
was calculated from serial measurements up to 72 h after
symptom onset. From these measurements, an area under
the curve was calculated, from at least five measurements.
Further details of this method have been described before
(5–7).
Statistics. A sample size of 592 patients, with 296 patients
in each treatment group was planned. A trial of this size has
a 80% power at an alpha level of 0.05 to show an increase
from the reported spontaneous reperfusion rate (TIMI flow
grade 2 or 3) of 18% to a reperfusion rate of at least 28% in
the high dose heparin group (4). Continuous data are
summarized as medians with 25th and 75th percentiles
unless otherwise stipulated. Selected baseline characteristics
and clinical outcome were compared between treatment
groups by the chi-square test or Fisher’s exact test for
discrete variables and by the Student t test for continuous
variables.
RESULTS
A total of 584 patients were included, of whom 299 were
randomized to high dose, and 285 patients to low dose/no
heparin. With regard to baseline characteristics as well as
outcome variables, there were no differences between the
low dose heparin and the no heparin patients, and, there-
fore, they are described together. The baseline characteris-
tics of the two groups were comparable and are summarized
in Table 1. In none of the patients was abciximab admin-
istered. Of the 584 patients, 161 (28%) patients were
transferred from other hospitals and received intravenous
heparin in the referral hospital before transportation to our
institution (Fig. 1). In these transferred patients, 87 patients
were randomized to the high dose intravenous heparin
(mean bolus 25, 690 IU), and 74 patients were randomized
to a low dose of 5,000 IU. The majority of patients (n 5
Abbreviations and Acronyms
HEAP 5 Heparin in Early Patency
LDH 5 lactate dehydrogenase
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
TIMI 5 Thrombolysis In Myocardial Infarction
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423) were admitted directly to our center; 211 received a
high dose bolus and 212 patients were randomized to no
heparin. During admission, 8 patients in the high dose
group died, and 12 patients in the low dose group died (p .
0.1). No patient died during transportation or during
coronary angiography and angioplasty. All deaths were of
cardiac causes. Recurrent MI occurred in both groups in 1%
of patients during the initial hospital stay.
Preprimary angioplasty patency rate (Table 2). In 65
patients (22%) in the high dose group versus 60 patients
(21%) in the low dose group, TIMI flow grade 2 or 3 was
observed (p . 0.1); TIMI flow grade 3 was observed in 38
(13%) vs. 24 (8%) (p 5 0.11). In the group of patients with
ischemic time ,200 min, there was a small trend in favor of
the high dose heparin group; 11% had TIMI flow grade 3
versus 6% in the low dose heparin group (p 5 0.09).
Outcome of primary angioplasty. In the high dose group,
278 (93%) patients underwent primary angioplasty; success
was achieved in 91% (TIMI flow grade 3 after angioplasty
and a residual stenosis ,50%). In 10 patients (3%) coronary
artery bypass surgery was indicated, and 11 patients with an
open infarct related artery (4%) were treated conservatively
after diagnostic angiography. In the low dose group, 266
patients (93%) underwent primary angioplasty with a suc-
cess rate of 88%. Coronary artery bypass surgery was
indicated in seven patients (3%), and 12 patients (4%) were
treated conservatively. Stent placement was performed in an
equal number of patients in both trial groups. In patients
with high dose heparin, stenting was performed in 95
patients (32%) and in 93 patients (32%) in the low dose/no
heparin group.
Left ventricular ejection fraction and enzymatic infarct
size. The mean LVEF (at day 4) was measured in 67% of
patients and was 45% (SD 11%) in both groups. Mean
enzymatic infarct size (LDHQ72) was 1,201 U (SD 1,091 U)
in the high dose group and 1,285 U (SD 1,082 U) in the low
dose group (p . 0.1). Measurements were available in 65%
in the high dose group and 70% in the low dose group.
Infarct size could not be calculated for patients in whom
insufficient blood samples could be taken, e.g., patients who
died shortly after admission or patients who were trans-
ferred back to the referral center soon after treatment.
Safety. No hemorraghic strokes were observed with high
dose heparin. A nonhemorraghic stroke occurred on day 4
after primary angioplasty in a single patient (body weight
94 kg) who had been treated with a bolus of 30,000 IU
heparin. No significant differences were found between the
groups in the number of patients requiring blood transfu-
sions (Table 3).
DISCUSSION
High dose heparin administration is safe, without excess of
bleeding complications but is not associated with a higher
rate of patency before primary angioplasty. The mechanism
of potential patency with high dose heparin is still unclear.
In a porcine model increasing dosages of heparin appeared
to decrease macroscopic thrombus (3). High dose heparin
also achieves lysis of experimental carotid artery thrombi (8).
Still, in the clinical setting of patients with acute MI,
regimes of high dose heparin have not been studied. In
almost 7,000 patients $65 years old who were not treated
with reperfusion therapy, the role of conventional dose
intravenous heparin was investigated in an observational
study (9). Heparin therapy was not associated with an
improved 30-day mortality rate, despite its common use in
this population.Figure 1. Flow Chart. CABG 5 coronary artery bypass grafting.
Table 1. Baseline Characteristics
High Dose
Heparin
(n 5 299)
Low Dose/
No Heparin
(n 5 285)
Age, yr (mean, SD) 59 (11) 58 (11)
Men 238 (80%) 219 (78%)
Anterior infarct
location
143 (48%) 142 (50%)
Killip class 1–2 277 (93%) 269 (95%)
Killip class 3–4 15 (5%) 9 (3%)
Previous angina 158 (53%) 142 (50%)
Previous MI 39 (13%) 29 (10%)
Previous CABG 6 (2%) 6 (2%)
Multivessel disease 160 (54%) 155 (55%)
Diabetes 27 (9%) 24 (9%)
Median time to
admission, min
(25th, 75th)
120 (75, 210) 120 (90, 170)
Median time to first
balloon, min (25th,
75th)
71 (55, 100) 72 (50, 102)
Median ischemic
time, min (25th,
75th)
195 (147, 304) 210 (150, 330)
There were no statistically significant differences between the two treatment groups.
CABG 5 coronary artery bypass grafting; MI 5 myocardial infarction.
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Heparin and thrombolysis. In the European Cooperative
Study Group trial, the use of intravenous heparin as an
adjunct to alteplase demonstrated a higher rate of patency in
the heparin group (2). Mortality was the same in both
groups. In the Global Use of Streptokinase and t-PA for
Occluded Coronary Arteries (GUSTO) trial, patients re-
ceiving streptokinase were randomized to receive either
delayed subcutaneous heparin or intravenous heparin
(10,11). No differences in clinical end points were found. A
meta-analysis of six randomized trials conducted with dif-
ferent thrombolytic drugs did not show benefit of heparin
after thrombolytic therapy (12).
Heparin and primary angioplasty. The HEAP pilot study
investigated the role of heparin without adjunctive treat-
ment of thrombolysis (4). In that study, the early patency
rate of the infarct related arteries was 51% versus 18% in a
matched control group. Although these findings were
promising, the results needed to be verified by a randomized
study. In this randomized HEAP trial, no significant
difference between the high dose and low dose heparin
group could be demonstrated, and the rate of patent arteries
is far lower than the reported level of patency achieved by
thrombolytic therapy (13). It is also lower than the rate
observed in the HEAP pilot study, which may suggest that
the patient group in the pilot study was a very selected
population. In addition, the results of the randomized trial
do not suggest any benefit in clinical outcomes such as
survival, primary angioplasty procedural success, enzymatic
infarct size or LVEF.
Study limitations. For logistic reasons (heparin bolus in
transfer patients was given in the referral hospital) treatment
allocation was not blinded. We do not expect that this resulted
in a bias since the review of the preprimary angioplasty
angiograms was blinded for treatment allocation. The knowl-
edge of outcome of randomization probably did not influence
the decision to give blood transfusion, as the indication of
blood transfusion is based on the level of hemoglobin.
Conclusions. There is no benefit of high dose intravenous
heparin on patency before primary angioplasty. To compen-
Table 2. Infarct Related Artery Patency Before Angioplasty
High Dose
Heparin
Low Dose/
No Heparin p Value
All patients n 5 299 n 5 285
TIMI flow grade 3 38 (13%) 24 (8%) .0.1
TIMI flow grade 2 27 (9%) 36 (13%) .0.1
TIMI flow grade 2/3 65 (22%) 60 (21%) .0.1
Ischemic time <200 min n 5 150 n 5 127
TIMI flow grade 3 17 (11%) 7 (6%) 0.09
TIMI flow grade 2 16 (11%) 12 (9%) .0.1
TIMI flow grade 2/3 33 (22%) 19 (15%) .0.1
Treatment delay >75 min n 5 125 n 5 111
TIMI flow grade 3 13 (10%) 6 (5%) .0.1
TIMI flow grade 2 12 (10%) 20 (18%) 0.06
TIMI flow grade 2/3 25 (20%) 26 (23%) .0.1
Presentation delay <120 min n 5 161 n 5 151
TIMI flow grade 3 20 (12%) 13 (9%) .0.1
TIMI flow grade 2 17 (11%) 17 (11%) .0.1
TIMI flow grade 2/3 37 (23%) 30 (20%) .0.1
TIMI 5 Thrombolysis In Myocardial Infarction.
Table 3. In-hospital Clinical Outcome
High Dose Heparin
n 5 299
Low Dose/No Heparin
n 5 285 p Value
TIMI flow grade 3 after angioplasty 254/278 (91%) 234/265 (88%) .0.1
Enzymatic infarct size (n 5 196) (n 5 201) .0.1
1,201 U (SD 1,091) 1,285 U (SD 1,082)
Left ventricular ejection fraction (n 5 197) (n 5 189) .0.1
44.7% 44.7%
Recurrent infarction 4 (1%) 2 (1%) .0.1
Major bleeding 30 (10%) 17 (6%) 0.07
Death 8 (3%) 12 (4%) .0.1
Major bleeding was defined as blood loss requiring blood transfusion.
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sate for door-to-balloon time, delay in patients scheduled
for primary angioplasty, other adjunctive therapies have to
be evaluated, together with efforts to improve patient
logistics in order to shorten time to reperfusion.
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